📈 Join us for LIVE TRADING action all day long in the 📈
Market Master’s trading room
Now, at absolutely no cost to our readers
✅Just one click, and you’re in!
A week ago, the market signaled the first daily downtrend in six months.
After hitting a low point on Monday last week, things have started to recover, mainly fueled by more optimism for AI and strong earnings from a couple of large tech companies.
We still have a lot of news to digest this week, so get ready for a wild ride ahead! 🎢
One of the bright spots in the market lately has been biotechs.
You know I am a huge fan of VKTX (a core holding of mine) and LLY, which have both been phenomenal performers.
When it comes to smaller stocks in this sector, we have already seen some amazing moves on the year.
I’ve already alerted you to some smaller biotechs that have moved 100% (or more) in a matter of days.
Today, I have an incredible new idea to share with you.
Pull up Cardiol Therapeutics Inc. (CRDL) on your platform right now, and let’s dig in…
Below, I posted a chart showing the daily action for nearly a year.
I want you to look at this chart so you can really get a perspective on the overwhelming bullish trend in place for this stock right now.
You will be hard-pressed to find a stock with the remarkable strength that we have seen for CRDL over the last several months.
In fact, you’ll notice that even with all of the market “chop,” CRDL has managed to more than double its price so far this year.
And I don’t see any reason to think that is over.
I highlighted two areas on the chart above, both showing what I call a “wedge pattern.”
Those are times when the trading range becomes extremely tight, and it is usually followed by a significant move.
When you have a rising wedge (like we see above), the breakout to the upside can be significant.
These moves can happen very quickly, so it is important to prepare and have a plan in place.
If you see the last time CRDL broke out of this wedge, it gained over 50% in just a few days.
I absolutely love this pattern.
There are not many opportunities like this in the market right now, so make sure you are keeping a close eye on CRDL.
I don’t think you need to be a technical trading expert to see the strong trend in place over the last several months, but if you want another opinion, look at what Barchart has to say about CRDL right now…
Their technical rating tool pegs CRDL with a pristine “100% BUY” right now.
It’s impossible to get any better than that.
As I said, this is a rare find, especially considering the market conditions we have at the moment.
Do not let this one slip away from you!
Company Overview
Cardiol Therapeutics Inc. (CRDL) is a clinical-stage life sciences company developing cannabidiol-based products to treat heart diseases.
In the wake of Covid, pericarditis and myocarditis have become household names.
Most people now know that these are inflammatory heart conditions that can significantly impact quality of life — and sometimes even prove fatal.
What they don’t know is that these conditions have very few effective treatments.
Partnering with healthcare heavyweights such as the Mayo Clinic and Cleveland Clinic, Toronto-based CRDL is working to address these significant unmet needs.
Importantly, many studies have shown that cannabidiol (better known as CBD) can inhibit multiple inflammatory pathways that are activated, particularly in cases of pericarditis and myocarditis.
The Company’s lead drug candidate is a novel prescription-strength cannabidiol product named CardiolRx™ that has already been granted FDA orphan drug designation (ODD) for treatment of pericarditis, and it is eligible for ODD for treatment of acute myocarditis.
CardiolRx™ has already progressed into two Phase II trials: the MAvERIC-Pilot study for the treatment of recurrent pericarditis (RP), and the ARCHER trial for the treatment of acute myocarditis (AM).
The MAvERIC-Pilot study is chaired by Dr. Allan Klein, who is also the director of the Center for the Diagnosis and Treatment of Pericardial Diseases at the Cleveland Clinic, one of the largest pericardial disease centers in the world.
CRDL picked the right man for the job. Dr. Klein was also the principal investigator for the Phase III trial of the first FDA-approved drug — Arcalyst — with an indication specifically for RP.
Not only does Arcalyst have an extraordinary price tag of $270,000 per patient per year, the drug can also suppress the immune system, potentially causing serious infections.
Nevertheless, despite debuting recently in 2021, Arcalyst brought in $233.2 million in 2023, and it’s expected to bring in $360–380 million this year.
Clearly, this market is ripe for competition.
CRDL achieved 100% enrollment in the MAvERIC-Pilot study in February and expects topline results this quarter.
Significantly, clinical development of Arcalyst proceeded on an accelerated 3-year timeline, and CRDL appears to be using the Arcalyst trials as a template for its own.
Their other Phase II trial — ARCHER — is chaired by Dr. Dennis McNamara, director of the heart failure/transplantation program at the University of Pittsburgh Medical Center, and the co-chair is Dr. Leslie Cooper, Jr., who is also chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine.
Right now, there are no FDA-approved therapies for acute myocarditis, so there is a major unmet need here – there are an estimated 46,000 AM cases each year in the US.
The trial recently exceeded 50% enrollment, and CRDL expects to reach full enrollment in Q3, ahead of the expected schedule.
CRDL has reported $34.9 million in cash and cash equivalents as of December 31, 2023, giving it a cash runway that it expects will fund operations into 2026.
Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: This is one of the best trading setups I have seen in a long time. With perfect “100% BUY” signals flashing, CRDL seems like a no-brainer to me to watch right now. This stock should be on the very top of your watchlist as we wait to see which direction the next breakout will take it.
To Your Success,
Jeff Bishop
👊 Make sure you are getting my mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out!
*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.
*ISSUER-PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars directly from Cardiol Therapeutics Inc. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Cardiol Therapeutics Inc, increased trading volume, and possibly an increased share price of Cardiol Therapeutics Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Cardiol Therapeutics Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.
TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.